Clinical trial registry record

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 13, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06325709
Last registry update
August 13, 2026
Status
Recruiting
Phase
Phase 1, Phase 2
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment
15
Countries
United States
Match confidence
90%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
15
Population
MALE · 18 Years to 75 Years
Duration
2024-04-17 to 2032-12-31
Intervention
Campath; Sirolimus; Base-edited hematopoietic stem and progenitor cells; Busulfan; Palifermin; Filgrastim; Plerixafor
Comparator
Not reported
Outcomes measured
To evaluate the safety of base-edited autologous CD34+ cells — Initiated from the time of the infusion of base-edited c…; To evaluate the efficacy of base-edited autologous CD34+ cells — Assessed 12 months post-infusion of base-edited cells; Evaluate the efficiency of base-editing. — Assessed 12-24 months post-infusion of base-edited cells; Evaluate the engraftment capability of base-edited hematopoietic stem progenitor cells. — Assessed 12-24 months post-in…; Evaluate the efficiency in restoring gp91phox expression. — Assessed 12-24 months post-infusion of base-edited cells; Evaluate efficacy in restoring NADPH oxidase function. — Assessed 12-24 months post-infusion of base-edited cells; Evaluate clinical efficacy — Assessed through study completion; Evaluate the stability of gene correction — Assessed through study completion
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 90% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 90%Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON